Description Please note that job descriptions are not exhaustive, and you may be asked to take on additional duties that align with the key responsibilities ment...

📢 Join us at @IP_London

We are recruiting a Clinical Research Fellow to join the #IP13AVIDITY team: RCT evaluating the role of PSMA PET/CT in directing treatment in patients w/ high-risk PCa (closing 15/04)

🔗 www.imperial.ac.uk/jobs/search-...

@londonprostate1.bsky.social @connorurol.bsky.social

‘Groundbreaking’ scan for men with prostate cancer could save lives Researchers hope the technology will help to create personalised treatment plans to prevent the disease becoming terminal

Thank you to @thetimes.com 📰for covering my first major grant success

- the £1.89M #IP13AVIDITY randomised trial testing PSMA PET defined and escalated treatment compared to standard of care for high-risk #prostatecancer @prostateukprofs.bsky.social

www.thetimes.com/uk/healthcar...

Great presentation from our PhD fellow Archana 👏🥇 at the RSM London showing the possibilities of immediate bladder pathology at time of TURBT using the Histolog FCM scanner! @archanagk.bsky.social @ip-london.bsky.social #RSMUrology #LaserComplete #TheUrologyFoundation

Working link to full open access article here: www.bmj.com/content/387/...

ICYMI: *30* year outcomes from SPCG-4
dx.doi.org/10.1056/NEJM...

RP vs. WW for clinically detected #prostatecancer reduces CSM 48% and *ACM* by 26%. NNT down to 6. Clear benefit to treatment of clinically detectable disease if (and only if) your pt has a very long life expectancy. #pcsm

It was a record meeting for Imperial Prostate at #BAUSOncology 2024 with presentations on prostate cancer screening, early detection, molecular imaging and discussion of many of our ongoing/upcoming trials from our fellows, lecturers, and consultants #ATLAS #AVIDITY #FLUORESCE #PACIFIC #TRANSFORM